I am a board-certified hematologist who specializes in the treatment of multiple myeloma and related plasma cell disorders including the precursor disorders monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma.

Together with my colleagues at MSK, I am focused on further optimizing treatment strategies for people with multiple myeloma. We offer a variety of modern treatments including clinic trials and novel immunotherapies. We are also working on measures to continue to improve patients’ quality of life while receiving treatment for multiple myeloma

Additionally, I have a particular interest in studying mechanisms and markers of progression from precursor disease to multiple myeloma. As part of this effort, we are developing targeted genomic tests for disease characterization and measurement of minimal residual disease. Better understanding of disease biology allows for better risk stratification and personalized treatment including early treatment for patients with high-risk precursor disease